New hope for stem cell transplant complication: drug trial targets Hard-to-Treat GVHD

NCT ID NCT05531786

First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 32 times

Summary

This study tests a drug called pacritinib for people with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't responded to at least two prior treatments. cGVHD is an immune system problem that can occur after a stem cell transplant, causing damage to multiple organs. Participants take pacritinib capsules daily for 6 to 12 months, with regular checkups to monitor safety and effectiveness. The goal is to find a better treatment option for this serious condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-••••

  • University of Miami

    RECRUITING

    Miami, Florida, 33101, United States

Conditions

Explore the condition pages connected to this study.